Glycochenodeoxycholic acid (Chenodeoxycholylglycine) (Synonyms: GCDCA, NSC 681056) |
| رقم الكتالوجGC34092 |
حمض الجليكوتشينوديوكسيكوليك (تشينوديوكسيكوليل جلايسين) (تشينوديوكسيكوليل جلايسين) هو حمض الصفراء يتكون في الكبد من الكينوديوكسيكولات والجليسين. يعمل كمنظف لإذابة الدهون من أجل الامتصاص ويتم امتصاصه في حد ذاته. يحفز حمض Glycochenodeoxycholic (Chenodeoxycholylglycine) (Chenodeoxycholylglycine) موت الخلايا المبرمج في الكبد.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 640-79-9
Sample solution is provided at 25 µL, 10mM.
Glycochenodeoxycholic acid is a bile salt formed in the liver from chenodeoxycholate and glycine; used to induce hepatocyte apoptosis in research.
Chenodeoxycholate is toxic to hepatocytes, and accumulation of chenodeoxycholate in the liver during cholestasis may potentiate hepatocellular injury. At a concentration of 250μM, glycochenodeoxycholate is more toxic than either chenodeoxycholate or taurochenodeoxycholate. Glycochenodeoxycholate cytotoxicity may result from ATP depletion followed by a subsequent rise in Ca2+. The rise in Ca2+ leads to an increase in calcium-dependent degradative proteolysis and, ultimately, cell death[1]. 4 h exposure of 50 μM GCDC induces apoptosis in 42% of hepatocytes. Intracellular PKC activity decreased to 44% of controls 2 h after exposure of hepatocytes to GCDC. GCDC-induced apoptosis is associated with decreases in total cellular PKC activity, which appear to be dependent on intracellular calpain-like protease activity[2].
GCDCA induces ER-related calcium release within about ten seconds. Significant increases in activities of calpain and caspase-12 are observed after 15 h of GCDCA treatment. Bip and Chop mRNA expressions are increased with the treated GCDCA dose and incubation time. Cytochrome c release from mitochondria peaks in about 2 h of incubation[3].
[1]. Spivey JR, et al. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest. 1993 Jul;92(1):17-24. [2]. Gonzalez B, et al. Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity. Mol Cell Biochem. 2000 Apr;207(1-2):19-27. [3]. Tsuchiya S, et al. Involvement of endoplasmic reticulum in glycochenodeoxycholic acid-induced apoptosis in rathepatocytes. Toxicol Lett. 2006 Oct 10;166(2):140-9.
Animal experiment: | Rats: The freshly isolated hepatocytes are preincubated for 2 h at a density of 1× 106 cells/mL in a mixture of William’s E medium supplement with 10% FBS. Isolated rat hepatocytes are incubated in William’s E medium with or without (used as a control) GCDCA (50, 100 and 300 μM), or TG (1, 2 and 5 μM) for 1-24 h[3]. |
References: [1]. Liang S, et al. Effect of quercetin 7-rhamnoside on glycochenodeoxycholic acid-induced L-02 human normal livercell apoptosis. Int J Mol Med. 2013 Aug;32(2):323-30. | |
| Cas No. | 640-79-9 | SDF | |
| المرادفات | GCDCA, NSC 681056 | ||
| Canonical SMILES | C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(NCC(O)=O)=O)([H])[C@@]3([H])[C@]([C@@]4([C@](C[C@H](O)CC4)([H])C[C@H]3O)C)([H])CC1 | ||
| Formula | C26H43NO5 | M.Wt | 449.62 |
| الذوبان | DMSO : ≥ 29 mg/mL (64.50 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2241 mL | 11.1205 mL | 22.241 mL |
| 5 mM | 444.8 μL | 2.2241 mL | 4.4482 mL |
| 10 mM | 222.4 μL | 1.1121 mL | 2.2241 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *















